|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Patients** | **Controls** | **Age** **(years)** | **Duration (years)** | **DMARDs****intake** | **Biologics****intake** | **GCs****current** | **Parameters assessed** | **Risk factors assessed**  |
| Zhu TY2013 (23) | 66(66F) | 66(66F) | 48.9±8.2 | 8.7(4.0-15.6) | 91% | 8% | 23% | aBMD, vBMD, cortical and trabecular structure, FEA | Menstrual status, swollen wrist(s) and recent exposure to glucocorticoids (6 Months Prior to the Study) |
| Zhu TY2014(24) | 50(50M) | 50(50M) | 61.1±8.5 | 12.3(5.5-9.0) | 88% | 4% | 36% | aBMD, vBMD, cortical and trabecular structure, FEA | ESR, DAS28, disease duration and SJCUse of GCs (cumulative dose, g and duration, months)IL1, IL6, TNFα |
| Kocijan R2014(25) | 90(60F) | 70(40F) | 53.6±12.8 | 9.5±8.0 | 68% | 69% | 44% | vBMD, cortical and trabecular structure | Age, disease duration, sex, height, weight, DMARD (y/n), Biologics (y/n), no GC versus GC, erosive disease (y/n) |
| Zhu TY 2011(21) | 100 (100F) | None | 53.4±9.3 | 9.1±7.8 | 93% | 7% | 19% | aBMD, vBMD, cortical and trabecular structure | Age, duration of disease, height, weight, menopausal status, smoking and drinking habit, fracture history, and fall CRP, DAS28, SJC, disease remission and erosive disease, HAQ, DMARDs (y/n),number of current DMARDs, biologics (y/n), Use of oral GC, cumulative dose, and duration  |

**Table 1: Studies with high resolution peripheral qualitative computed tomography assessment at the distal radius in patients with RA**

Results are mean ±SD or median (interquartile range) unless otherwise indicated.

Abbreviations: F: female, M: male, DMARDs: disease modifying anti-rheumatic drugs, GCs: Glucocorticoids, aBMD: areal bone mineral density, vBMD: volumetric bone mineral density, FEA: finite element analysis, ESR: erythrocyte sedimentation rate, DAS: disease activity score, SJC: swollen joint count, IL1: interleukin 1, TNFα: tumor necrosis factor alpha, CRP: C-reactive protein, HAQ: health assessment questionnaire.